Man in western Wisconsin dies from injuries after being hit by car while crossing street
ELLSWORTH, Wis. (WFRV) – A 74-year-old Wisconsin man died from injuries suffered after being hit by a car while crossing the street in a marked crosswalk.
The Ellsworth Police Department reported that officers responded to a vehicle versus pedestrian crash around 3:14 p.m. on Thursday near the intersection of Highway 10, Main Street and Beulah Street in Ellsworth.
Man hit by stray bullet while traveling in Wisconsin, deputies investigating
Initial investigation details state that a 2009 Toyota Camry was heading westbound when the driver, 78-year-old Daniel Hayes of Ellsworth, hit a person crossing the street.
The 74-year-old pedestrian was identified as Kenneth Wilson of Ellsworth. Wilson was reportedly crossing through a marked crosswalk at the time of the crash. He was taken to a Minnesota hospital with life-threatening injuries, where he later died.
Wisconsin driver with 3 unrestrained children under age of 5 arrested for OWI after crash
The crash is still under investigation.
No additional details were provided.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Everything you need to know about headaches for Headache Awareness Month
NEW HAVEN, Conn. (WTNH) — June is Headache Awareness Month. In today's health headlines, we discuss what to know about the most common headache types, how to tell them apart, and tips for preventing a tension headache. Dr. Vanessa Cooper, Yale Medicine neurologist specializing in headaches and assistant professor at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss. Watch the video above to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
‘Impaired drivers are out at all times of the day': 2 Wisconsin drivers who admitted to recent meth use arrested for OWI in same day
RICE LAKE, Wis. (WFRV) – Officers in one northwestern Wisconsin city arrested two drivers for OWI around midday on Thursday who admitted to recent meth use, and are reminding residents that impaired drivers are out at all times of the day. A release from the Rice Lake Police Department states that officers arrested two drivers on June 5, one at 10:35 a.m. and the other at 12:10 p.m., for their seventh and sixth OWI offenses, respectively. 'Remove or cover valuables in vehicle:' Police in Wisconsin issue warning after firearm reported stolen from parked car After the first traffic stop in Rice Lake that morning for 'multiple reasons,' including a stop sign violation, the officer noticed signs of impairment. The driver allegedly admitted to recent THC and methamphetamine use and was subsequently arrested for the 7th OWI offense. Shortly after, around 12:10 p.m., another officer conducted a traffic stop for a seatbelt violation. The driver reportedly showed signs of impairment, and a K9 gave a positive alert on the vehicle. The second driver also admitted to recent methamphetamine use and was arrested for their 6th OWI offense. Officers also noted that methamphetamine was found in their vehicle. Two men from Romania arrested in Wisconsin for ATM skimmer operation 'Impaired drivers are out at all times of the day,' officers noted in the release. 'Please be responsible and safe.' No additional details were provided. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 membrane transporter and reduced vascular calcification in animal models of CKD BOSTON, June 06, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., ('Rectify') a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today showcased new data from its cardiorenal program with its ABCC6-targeting PFM, RTY-822. The results were presented in an oral presentation during the European Renal Association (ERA) 2025 Congress, taking place in Vienna, Austria, June 4 – 7, 2025. 'These translational results demonstrate that Rectify's PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,' said Rajesh Devraj, Ph.D., President and Chief Executive Officer of Rectify. 'We believe the strength of these data underscores the potential of our approach to offer a novel and differentiated therapeutic strategy to treat renal dysfunction and injury, as well as address vascular calcification driving cardiovascular disease. We are committed to continuing to advance meaningful therapies for patients with CKD and serious cardiovascular conditions.' Robert Hughes, Ph.D., Chief Scientific Officer of Rectify, added, 'Enhancing the function of ABCC6 holds the potential to address key drivers of vascular calcification and tubular dysfunction seen in CKD. With demonstrated on-target engagement, RTY-822 shows significant promise to reduce CKD-associated calcium deposits in arterial walls, a well-established contributor to cardiovascular morbidity and mortality seen in patients with CKD, and remarkably, also improves glomerular function and tubular injury. The translational readiness of this program makes it a compelling de-risked asset with the potential to address CKD and multiple cardiovascular indications.' Title: A Positive Functional Modulator of ABCC6 Decreases Vascular Calcification and Improves Kidney Function in a Rat Adenine Diet Model of Chronic Kidney DiseaseAbstract Number: 1723 Presenter: John Miller, Ph.D. Session: Chronic Kidney Disease, Focused Oral Room 4Date and Time: Friday, June 6, 2025, 8:51 a.m. – 8:57 a.m. CEST In CKD, reduced ABCC6 activity or expression may lead to lower PPi levels, contributing to pathological calcification in blood vessels and kidneys. Restoring ABCC6 function or enhancing its expression offers a new and compelling therapeutic strategy to prevent the progression of CKD towards end-stage renal disease in addition to reducing large vessel calcification, a major driver of cardiovascular complications in CKD. Key findings RTY-822, an orally administered PFM targeting ABCC6 increased both ABCC6 protein expression and plasma PPi levels in primary human hepatocytes, supporting its proposed mechanism of action In a rat model of CKD and vascular calcification induced by an adenine-enriched diet with calcitriol supplementation: RTY-822 treatment led to statistically significant reductions in vascular calcification in the aorta and the femoral arteries After a six-week treatment course, RTY-822 improved glomerular and tubular kidney functions, with statistically significant reductions in serum creatinine, urea, and cystatin C, and an improved estimated glomerular filtration rate (eGFR) Calcium accumulation in the kidney was also significantly reduced Kidney injury biomarkers were reduced, including a significant decrease in plasma KIM-1 and urinary Lipocalin-2 (NGAL) levels In rats fed an adenine-rich diet without calcitriol supplementation, treatment with RTY-822 resulted in: Improved glomerular and tubular kidney functions Reduced serum creatinine and cystatin C levels Increased eGFR Reduced urinary NGAL levels, a biomarker of acute kidney injury The presentation is available on the Rectify website at About Rectify Pharmaceuticals, Inc. ('Rectify') Rectify is advancing Positive Functional Modulators (PFMs), a novel class of oral, small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases. Rectify's PFMs have potential to modulate the activity of wild-type and mutated membrane-bound proteins, a historically difficult challenge with a small molecule approach. The Company's breakthrough product platform enables efficient and rapid discovery of first- and best-in-class small molecule therapies with the potential to address membrane protein dysfunction for treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases. Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund. For more information, please visit or follow us on X and LinkedIn. ContactMediaJonathan PappasLifeSci Communicationsjpappas@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
